Amylyx

Amylyx Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is committed to the ongoing development of new therapeutic drugs for ALS and other neurodegenerative diseases. These diseases are characterized by neuroinflammation and neuronal cell death. The company's candidate drug, AMX0035, is an oral proprietary combination of two known drugs mixed in a specific proportion. It targets the characteristic neuroinflammation and neuronal cell death seen in these diseases, aiming to prevent neuronal cell death and the generation of toxic neuroinflammation.